SAT-341 Pharmacology and Metabolism of GLL398 an Oral Selective Estrogen Receptor Degrader for Endocrine Therapy of Breast Cancer

Selective estrogen receptor degrader (SERD) has proven clinically effective in treating advanced or metastatic breast cancer since the approval of fulvestrant by FDA in 2002. Recent expansion of indications as a first line monotherapy and as combination therapy with CDK4/6 inhibitors further demonst...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Endocr Soc
Hlavní autoři: Guo, Shanchun, Hossain, Ahamed, Zhang, Changde, Mottamal, Madhu, Liu, Jiawang, Wiese, Thomas, Wang, Guangdi
Médium: Artigo
Jazyk:Inglês
Vydáno: Endocrine Society 2019
Témata:
Tumor Biology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6552000/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SAT-341
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky